Active	Status	Sponsor type	Region	Phase	Filter
5 Active 2 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kato, Takeshi
ALTAIR, NCT04457297: Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection	Recruiting	3	240	Japan, RoW	trifluridine and tipiracil, Placebo	National Cancer Center Hospital East, Alpha-A, Inc.	Colorectal Neoplasms, Trifluridine and Tipiracil, Circulating Tumor DNA	05/23	12/23
JCOG1801, NCT04288999: Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer	Recruiting	3	110	Japan	Chemotherapy, CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV, Preoperative radiotherapy, Capecitabine plus radiotherapy, Procedure, Surgery	National Cancer Center Hospital East, Japan Clinical Oncology Group, Japan Agency for Medical Research and Development	Rectal Cancer Recurrent	08/25	10/28
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer	Recruiting	3	400	Europe, Canada, Japan, US, RoW	tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil	Seagen Inc., Merck Sharp & Dohme LLC	Colorectal Neoplasms	08/25	04/28
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer	Recruiting	3	711	Europe, Canada, Japan, US, RoW	Dostarlimab, CAPEOX, FOLFOX	GlaxoSmithKline	Colonic Neoplasms, Neoplasms, Colon	12/28	12/30
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer	Recruiting	2	150	Europe, Canada, Japan, US, RoW	Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A	GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd	Neoplasms, Rectal	11/26	10/29